Fusion Antibodies to Humanize Avipero’s integrin antibody platform

Share Article

Fusion Antibodies Ltd has today announced a collaboration with the regenerative medicine company Avipero Ltd for humanization of their integrin antibody platform. The antibody engineering and humanization program partnered with Fusion Antibodies relates to the humanization of beta integrin targeting antibodies under development by Avipero for tissue repair and viral infections.

Fusion Antibodies and Avipero Announce Collaboration

Fusion Antibodies and Avipero Announce Collaboration

This significant development will help strengthen the momentum of our development program and allow recent advances to progress seamlessly.

The partnership of Avipero and Fusion comes following new developments in Avipero’s R&D and a record breaking year for Fusion Antibodies’ Humanization service. "We are excited to be working with Avipero on their integrin antibodies and confident that Fusion Antibodies CDRx Humanization Platform will deliver high quality humanized antibodies that will accelerate the project into the clinic," says Dr Richard Buick, Chief Technical Officer of Fusion Antibodies.

“This significant development will help strengthen the momentum of our development program and allow recent advances to progress seamlessly,” says Dr. Rehab AlJamal-Naylor, Chief Scientific Officer of Avipero Ltd. The private biopharmaceutical company Avipero Ltd is focused on the development of novel allosteric integrin targeting antibodies for unmet clinical needs. The principal clinical indication for its R&D is Parkinson’s disease. Avipero has recently expanded its platform to include orphan viral infections.

The project is due to start in the next few weeks with early data expected over the summer.

About AVIPERO Ltd.
AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. The principal indication for Avipero’s development is Parkinson’s disease. Avipero’s platform has demonstrated efficacy in other conditions such chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.

About Fusion Antibodies
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 13+ years of experience in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Forward Looking Statements
Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as “believes”, “may”, “plans”, “will”, “estimate”, “continue”, “anticipates”, “intends”, “expects”, and similar expressions. While forward-looking statements represent management’s outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO’s early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO’s dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Glover

Dr. Rehab AlJamal-Naylor
Email >
Follow >
Fusion Antibodies
Like >
Fusion Antibodies Ltd

Follow us on
Visit website